Lexicon Pharmaceutcl (LXRX) Stock Price, Quote & News

Company Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its...

Industry: Biotechnology

Sector: Healthcare

Phone: 281 863 3000

Fax: 281 863 8088

Website: www.lexpharma.com

Address:

2445 Technology Forest Boulevard, 11th Floor, The Woodlands, United States

PAMPmasterflex Oct. 25 at 7:28 PM

$LXRX Stop getting upset at people for posting opinions, just because their opinions are not what you want to hear. His opinions are just as valid as any of these other people with their heads in the sand posting empty hopium posts, acting like there isn't any cause for concern with Lexicon. I'm long here, and there is plenty to be concerned about, this is by no means a slam dunk investment. Objective, rational people want to hear both sides of the story, not just the side they're rooting for.

1 · Reply

Pit1908 Oct. 25 at 1:39 PM

$LXRX Will the quarterly RESULTS be released on October 30th or September 11th? 🤔

2 · Reply

KurwaMac Oct. 25 at 12:17 PM

$LXRX

0 · Reply

Henry20feb_ Oct. 25 at 11:42 AM

$LXRX Don't forget Lexicon's Cost reduction plan / Focus on clinical development / Partnership with Viatris (?).

0 · Reply

Henry20feb_ Oct. 25 at 11:32 AM

$LXRX From October 25, 2025 onward, the key upcoming events for Lexicon Pharmaceuticals are: - FDA feedback on Zynquista; - Start of Phase 3 studies for pilavapadin (LX9211); - IND submission for LX9851 These upcoming events could have a significant impact on Lexicon Pharmaceuticals’ stock price and outlook. (Thanks to ChatGPT)

0 · Reply

Iman133 Oct. 25 at 10:33 AM

$LXRX https://www.sec.gov/Archives/edgar/data/1792044/000114036125039263/ny20055082x771_def14a.htm

0 · Reply

Softclothes Oct. 25 at 4:54 AM

$LXRX $LXRX Clearly people here do not agree with whatever you are writing. It is your prerogative to sell if you wish, but why waste your time trying to trash it afterwards? It doesn't profit you to do so, you just waste time. It's no ones job here to convince you that you're wrong, there's enough information shared about it out there for you to make that decision yourself. It has been the best investment decision I have made on the market so far, and nothing is certain but I will absolutely take my chances here. Good luck finding anything with such value and potential. Once I decide to sell, I won't spend any time writing about it afterwards. Move on. I think you are being foolish with both your decision and your behaviour afterwards.

1 · Reply

pi22dv7 Oct. 25 at 1:40 AM

$LXRX What’s the near term catalyst? I couldn’t find any, is this dead money?

1 · Reply

blaack_rules Oct. 25 at 1:18 AM

$LXRX $LXRX then move on to greener pastures dude instead of hanging around needling the longs. Better yet, take that big bucks windfall you made on that Massive 15k share stake and sell short a few k. What the hey, you could double your money when it goes to $0, buy a used Tesla.

1 · Reply

KurwaMac Oct. 24 at 11:31 PM

$LXRX homie believes he has influence over the stock market and has a desire for the price to drop.

1 · Reply

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit

Oct 8, 2025, 7:59 AM EDT - 17 days ago

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

Sep 22, 2025, 4:00 PM EDT - 4 weeks ago

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Sep 17, 2025, 7:00 AM EDT - 5 weeks ago

Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings

Sep 11, 2025, 8:30 AM EDT - 6 weeks ago

Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings

Sep 8, 2025, 8:30 AM EDT - 6 weeks ago

Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Sep 4, 2025, 8:30 AM EDT - 7 weeks ago

Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025

Sep 3, 2025, 7:36 PM EDT - 7 weeks ago

Lexicon Pharmaceuticals, Inc. (LXRX) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 3, 2025, 8:30 AM EDT - 7 weeks ago

Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025

Sep 2, 2025, 8:30 AM EDT - 7 weeks ago

Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress

Aug 27, 2025, 8:30 AM EDT - 2 months ago

Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences

Aug 6, 2025, 12:39 PM EDT - 2 months ago

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 7:30 AM EDT - 2 months ago

Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 31, 2025, 8:00 AM EDT - 3 months ago

Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 23, 2025, 8:00 AM EDT - 3 months ago

Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 18, 2025, 8:00 AM EDT - 3 months ago

Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)

Jun 23, 2025, 8:00 AM EDT - 4 months ago

Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Jun 18, 2025, 8:30 AM EDT - 4 months ago

Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)

May 29, 2025, 8:00 AM EDT - 5 months ago

Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 19, 2025, 8:00 AM EDT - 5 months ago

SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology

May 13, 2025, 9:47 PM EDT - 5 months ago

Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:00 PM EDT - 5 months ago

Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates

May 6, 2025, 4:30 PM EDT - 6 months ago

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

May 6, 2025, 8:00 AM EDT - 6 months ago

Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

Apr 25, 2025, 9:00 AM EDT - 6 months ago

Top 2 Health Care Stocks That May Crash This Month

Apr 2, 2025, 8:00 AM EDT - 7 months ago

Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 28, 2025, 10:09 AM EDT - 7 months ago

Lexicon Pharmaceuticals Shares Soar on Novo Nordisk Licensing Deal

NVO

Mar 28, 2025, 9:02 AM EDT - 7 months ago

Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk

NVO

Mar 28, 2025, 7:30 AM EDT - 7 months ago

Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

Mar 7, 2025, 8:30 AM EST - 8 months ago

Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025

Mar 6, 2025, 10:52 PM EST - 8 months ago

Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 4:00 PM EST - 8 months ago

Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 4, 2025, 4:15 PM EST - 8 months ago

Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Mar 3, 2025, 7:00 AM EST - 8 months ago

Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

Mar 2, 2025, 4:13 PM EST - 8 months ago

Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

Feb 18, 2025, 8:00 AM EST - 8 months ago

Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)

Jan 21, 2025, 8:00 AM EST - 9 months ago

Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain

Jan 2, 2025, 8:00 AM EST - 10 months ago

Lexicon Appoints Scott Coiante as Chief Financial Officer

Dec 20, 2024, 4:46 PM EST - 11 months ago

US FDA declines to approve Lexicon Pharma's add-on diabetes drug

Dec 20, 2024, 4:30 PM EST - 11 months ago

Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)

Nov 26, 2024, 8:00 AM EST - 11 months ago

Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

Nov 25, 2024, 4:15 PM EST - 11 months ago

Lexicon Pharmaceuticals to Participate in December Investor Conferences

Nov 22, 2024, 7:47 AM EST - 1 year ago

Lexicon Pharmaceuticals to cut workforce by 60% to focus on drug development

Nov 22, 2024, 7:32 AM EST - 1 year ago

Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA

Nov 20, 2024, 4:05 PM EST - 1 year ago

Lexicon Appoints Ivan H. Cheung to Board of Directors

Nov 12, 2024, 8:39 PM EST - 1 year ago

Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 1 year ago

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 6, 2024, 8:00 AM EST - 1 year ago

Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference

Nov 5, 2024, 4:05 PM EST - 1 year ago

Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease

Oct 31, 2024, 6:54 PM EDT - 1 year ago

Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease

PAMPmasterflex Oct. 25 at 7:28 PM

1 · Reply

Pit1908 Oct. 25 at 1:39 PM

$LXRX Will the quarterly RESULTS be released on October 30th or September 11th? 🤔

2 · Reply

KurwaMac Oct. 25 at 12:17 PM

$LXRX

0 · Reply

Henry20feb_ Oct. 25 at 11:42 AM

$LXRX Don't forget Lexicon's Cost reduction plan / Focus on clinical development / Partnership with Viatris (?).

0 · Reply

Henry20feb_ Oct. 25 at 11:32 AM

0 · Reply

Iman133 Oct. 25 at 10:33 AM

$LXRX https://www.sec.gov/Archives/edgar/data/1792044/000114036125039263/ny20055082x771_def14a.htm

0 · Reply

Softclothes Oct. 25 at 4:54 AM

1 · Reply

pi22dv7 Oct. 25 at 1:40 AM

$LXRX What’s the near term catalyst? I couldn’t find any, is this dead money?

1 · Reply

blaack_rules Oct. 25 at 1:18 AM

1 · Reply

KurwaMac Oct. 24 at 11:31 PM

$LXRX homie believes he has influence over the stock market and has a desire for the price to drop.

1 · Reply

Jbjb90 Oct. 24 at 10:58 PM

$LXRX Thought you sold and left 👋 comparing studies and decisions under past leadership to the new regime is apple to oranges. Grew up in chicago, cubs were terrible forever and by your logic because theyve been bad have to be bad, new management, new GM, world series in 2016. A stretch of comparison but my point is this, an organization under new management and guidance can not be compared to the decisions of failed past leaders. ZI believe in Extons vision, if you dont then good on you for selling, my average is .85 cents, i bet we never test those lows and you can mock me and repost this. I remember you talked shit leading up to getting above a dollar, you swore it would never happen, but here we sit. 2-3 bucks by year end, lets go 💪

2 · Reply

Jbjb90 Oct. 24 at 10:45 PM

$LXRX opening price 1.44, closed at 1.42. Boring low volume week, in my opinion expect more of the same til news. Leading up to the data last week it was a huge volume week on the way up, that was less about the data and more about the anticipation a deal on pilavapidin could be announced at the same time or shortly after. Nothing came to be and here we sit, my guess is a partner wants phase 3 acceptance, Exton said deep discussions with partnerS, plural. Another guess would be original partner said they want phase 3 guarantee or some other stipulation and they reached out elsewhere and got similiar feedback, either way there is interest. If youre unhappy with your position as i was buy the dip, hold the rest, and enjoy the ride, goodnluck all!

0 · Reply

GenericPoster Oct. 24 at 9:39 PM

$LXRX Short interest for the 1H of October is out after close today and shows a drop of 466k or 1.7% leaving over 26.8 million shares short. LXRX shares closed at $1.35 on Sept 30th and at $1.53 on October 15, 2025. These next two weeks may not bring news but I wonder if the shorts have been adding since it was taken down for options expiration. And, other than one larger up day, LXRX has been mostly range bound here in the lower $1.4x range. When we do have the earnings report and conference call, we may get some updates on earnings the next $39 million milestone from Novo (turn over IND data/info but Novo to file the IND with FDA), perhaps a reasonable earnings report since they did not recognize the full $45 million 2Q (but most of it) and then word on Inpefa trials for HCM and partnership programs for Pilavapadin. I still don’t know what the shorts are waiting on to cover as this was $0.40 in March. From: https://www.nasdaq.com/market-activity/stocks/lxrx/short-interest

0 · Reply

utapartment26 Oct. 24 at 8:58 PM

$LXRX Sota is dead in the water, will make a few bread crumbs of revenue but that's it. Viatris is applying for regulatory approval to sell it in such giant markets as the UAE, Saudi Arabia and Canada ..aka...peanuts. LX9851 will never make it to the market, because there is far too much competition on the horizon, 10 drugs are already approved for weight loss, 150 more in pharma pipelines. In 8 years, if 9851 gets to the market, it won't be able to corner the market due to the countless other drugs already available. And good luck with Pilavapadin, if their study design for Pilavapadin is anything like it was for Sota (diabetes) it's going to crash and burn. The entire future of this company is depending on Pilavapadin, quite literally.

3 · Reply

Softclothes Oct. 24 at 8:44 PM

$LXRX This didn’t get posted to the board but my offer stands if anyone is interested.

1 · Reply

alcat1973 Oct. 24 at 8:21 PM

$LXRX Did I write Here something...been a long week.

0 · Reply

alcat1973 Oct. 24 at 8:19 PM

$LXRX No news is good news for blood tests, and scans but not for Lexi. We really need to here something...anything. This up a penny-down a penny is not what I signed up for. Hoping Christmas comes early this year. Back at it on Monday. GLTA

3 · Reply

Iman133 Oct. 24 at 8:16 PM

$LXRX Interestingly, we moved 0.00% this week

0 · Reply

cobragene Oct. 24 at 7:36 PM

$LXRX For everyone wondering why Ray is not buying or selling a single share in over 11 months. If a company came to Lexi about a merger or buyout the time frame (typically 6 months to 2 years) would keep him from trading LXRX. I'm not saying this is what is happening and the rest of us would not need to be notified until a definitive agreement is reached. But it does beg the question as to why he hasn't DCA when Lexi was .30 Just things to ponder prior to a weekend....

2 · Reply

Iman133 Oct. 24 at 7:22 PM

$LXRX Another day with low vol …

0 · Reply

cobragene Oct. 24 at 7:05 PM

$LXRX With Sotagliflozin in the pivotal Phase 3 SONATA HCM study, and Zynquista going for round 2 at the FDA, Let's not forget Novo Nordisk getting worldwide rights to LX9851 with up to 1 billion in royalties. Who in their right mind would be short Lexi. One Monday morning we'll wake up to news and wonder why we didn't own more alot more. GLTA and have a Great Weekend.

1 · Reply

Dooright Oct. 24 at 6:08 PM

$LXRX Again… 100% correct! 👍 Doc C. 🤓

1 · Reply

Market Cap	508.76M
Revenue (ttm)	31.08M
Net Income (ttm)	-200.40M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-644.79%
Debt to Equity Ratio	0.43

Volume	1,010,000
Avg Vol	2,313,242
Day's Range	N/A - N/A
Shares Out	363.40M
Stochastic %K	27%
Beta	1.23
Analysts	Sell
Price Target	$2.75